Abstract
The epidemiology of the different types of primary and secondary malignant neoplasms of the liver and biliary tract are thought-provoking because the etiological possibilities seem easy to document in view of their marked geographical differences. Primary liver cancer (both hepatocellular and cholangiocellular carcinoma) have their maximum incidence and prevalence in those areas of the world and in those populations that have the lowest incidence and prevalence of primary large bowel cancer. Primary liver cancer is a common disease in the black population in Africa (south of the Sahara) and throughout the Far East. It is significant that the caucasians in southern Africa have a low incidence of primary liver cancer, comparable to occurrence rates in the United States. The occurrence rates of secondary cancer in the liver is proportional to the incidence of the primary cancer. Primary large bowel cancer (with resultant metastases to the liver) occurs commonly in the United States and Europe. Other common malignant neoplasms that metastasize to the liver are cancer of the stomach, pancreas, breast, and lung.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Makk L, Delmor F, Creech JL (Jr), Ogden LL, Fadell EH, Songster CL, Clanton J, Johnson MN, Christopherson WM. Clinical and morphological features of hepatic angiosarcoma in vinyl chloride workers. Cancer 37:149–163, 1976.
Linsell CA, Peers FG. Field studies on liver cell cancer. In Origins of Human Cancer, Book A, Incidence of Cancer in Humans, Hiatt HH, Watson JD, Winsten JA (eds). Cold Spring Harbor: Cold Spring Harbor Laboratory, 1977, pp. 549–556.
Higginson J, Terracini B, Agthe C. Nutrition and cancer: ingestion of foodborne carcinogens. In Cancer Epidemiology and Prevention, Current Concepts, Schottenfeld D, (ed). Springfield: CC Thomas, 1975, pp. 177–206.
Glassberg AB, Rosenbaum EH. Oral contraceptives and malignant hepatoma. Lancet 1:470, 1976.
Johnson FL, Feagler JR, Lerner KG, Majerus PW, Siegel M, Hartman JR, Thomas CD. Association of androgenic anabolic steroid therapy with development of hepatocellular carcinoma. Lancet 2:1273–1276, 1972.
Falkson G, Maclntyre JM, Schutt AJ, Coetzer BJ, Johnson LA, Simson IW, Douglass HO (Jr). Neocarzinostatin versus m-AMSA or adriamycin in hepatocellular carcinoma. J of Clin Oncol 2:581–584, 1984.
Falkson G, Maclntyre JM, Moertel CG, Johnson LA, Scherman RC. Primary liver cancer: an eastern cooperative oncology group (ECOG) trial. Cancer 54:965–969, 1984.
Lavin P, Mittelman A, Douglass H (Jr), Engstrom P, Ciaassen D. Survival and response to chemotherapy for advanced colorectal adenocarcinoma: an eastern cooperative oncology group report. Cancer 46: 1536–1543, 1980.
Cohen L, Shapiro MP, Keen P, Cohen A, DeMoor MG. Experimental radiotherapy of abdominal cancer: radiosensitivity of liver tumours. Br J Radiol 27:402, 1954.
Falkson G. The treatment of liver cell cancer. In Liver Cell Cancer, Cameron HM, Lirisell DA, Warwick GP, (eds). Amsterdam: Elsevier, 1976.
Cochrane AMG, Murray-Lyon IM, Brinkley DM, Williams R. Quadruple chemotherapy versus radiotherapy in treatment of primary hepatocellular carcinoma. Cancer 40:609, 1977.
Smoran GL. Radiation therapy of carcinoma of the gallbladder and biliary tract. Cancer 40:1422, 1977.
Falkson G, Gelman RS, Tormey DC, Cummings FJ, Carbone PP. The eastern cooperative oncology group (ECOG) experience with cyclophosphamide, adriamycin and fluorouracil (CAF), in patients with metastatic breast cancer. Submitted for publication, 1985.
Falkson G, Moertel CG, Lavin P, Pretorius FJ, Carbone PP. Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial. Cancer 42:2149–2156, 1978.
Geddes EW, Falkson G. Malignant hepatoma in the Bantu. Cancer 25:1271–1278, 1970.
Oon CJ: Treatment of primary liver cancer in the Far East. In Primary Liver Cancer in Man, Falkson G, Coetzer BJ, (eds). New York: Marcel Dekker, in press.
Cheng E, Lightdale C, Young C, Yagoda A, Former J, Golbey R. Phase II trial of (m-AMSA) 4′-(9-acridinylamino) — methanesulfon-m-anasidide in primary liver cancer. Am J Clin Oncol 6:211–213, 1983.
Olweny CLM, Toya T, Katongole-Mbidde E, Mugerwa J, Kyalazi SK, Cohen H. Treatment of hepatocellular carcinoma with adriamycin: preliminary communication. Cancer 36:1250–1257, 1975.
Olweny CL, Katongole-Mbidde E, Bahendeka S, Otim D, Mugerwa J, Kyalwazi SK. Further experience in treating patients with hepatocellular carcinoma in Uganda. Cancer 46:2721–2722, 1980.
Falkson G, Maclntyre J, Moertel CJ. ECOG experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 54:970–977, 1984.
MacDonald JS, Gunderson LL, Adson MA. Cancer of the hepatobiliary system. In Cancer Principles and Practice of Oncology, De Vita VT, Hellman S, Rosenberg SA, (eds). Philadelphia and Toronto: JB Lippincott, 1982.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Martinus Nijhoff Publishing, Boston/Dordrecht/Lancaster
About this chapter
Cite this chapter
Falkson, G., Coetzer, B. (1985). Natural History of Liver Cancer. In: Bottino, J.C., Opfell, R.W., Muggia, F.M. (eds) Liver Cancer. Developments in Oncology, vol 30. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2593-2_2
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2593-2_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9625-6
Online ISBN: 978-1-4613-2593-2
eBook Packages: Springer Book Archive